Lantheus Earnings Call Maps Painful Reset Before 2027

Lantheus Holdings Inc ((LNTH)) has held its Q4 earnings call. Read on for the main highlights of the call.

Lantheus Holdings Inc.’s latest earnings call struck a cautious but constructive tone. Management showcased strategic wins in radiodiagnostics, highlighted solid product leadership, and laid out a clear roadmap toward a bigger portfolio from 2027. Yet they also acknowledged near-term revenue pressure, margin compression, and execution risk that temper the growth story.

Steady Revenue, Limited Growth in 2025

Lantheus reported Q4 2025 revenue of $406.8 million, up 4% year over year, and full‑year revenue of $1,541.6 million, a modest 0.5% increase. The company emphasized its scale and reach by noting that its products impacted about 7 million patients over the year.

Portfolio Shift Through M&A and SPECT Exit

The company continued reshaping its portfolio with the acquisitions of Neuraceq and OCTEVY, both focused on PET imaging in neurology and oncology. It also announced the divestiture of its legacy SPECT business effective Jan. 1, 2026, sharpening its focus on higher‑growth PET radiodiagnostics.

Neuraceq Emerging as a Growth Engine

Neuraceq, a beta‑amyloid PET tracer for neuroimaging, delivered $31 million in Q4 and $51.4 million since its late‑July acquisition. Management expects triple‑digit inorganic growth for Neuraceq in 2026 as it adds six more manufacturing sites and broadens market access.

Core Franchises PYLARIFY and DEFINITY Stay Dominant

PYLARIFY remains the market leader in PSMA PET imaging with volumes up about 4% year over year in Q4 despite revenue headwinds. DEFINITY, the company’s cardiac ultrasound contrast, generated more than $85 million in Q4, holds over 80% market share, and is expected to grow in the low‑ to mid‑single digits in 2026.

Late-Stage Pipeline Targets 2027 Impact

Lantheus outlined a packed regulatory calendar for 2026, including PDUFA dates for a new PSMA PET formulation, OCTEVY, MK‑6240, and the Lutathera‑like PNT2003. Management stressed that while these catalysts are near term, the real commercial impact is expected to ramp meaningfully from 2027 onward.

2026 Outlook: Investment Year With Slower Top Line

For 2026, Lantheus guided worldwide net revenue to $1.40–$1.45 billion and a gross margin around 65.5%, with EPS of $5.00–$5.25. The outlook embeds higher R&D at 10%–11% of revenue and increased commercial spend to prepare for multiple launches, making 2026 an investment‑heavy transition year.

Execution Playbook for PSMA Transition

Management detailed a regional, rolling transition to the new F‑18 PSMA formulation beginning in Q4 2026. The strategy centers on securing coding and payer coverage, winning transitional pass‑through status, and leveraging its PMF network to avoid supply disruption and underpin growth into 2027.

Capital Deployment and Balance Sheet Flexibility

Lantheus returned $100 million to shareholders in Q4 via repurchases of 1.77 million shares and still has $200 million remaining under its authorization. The company ended the year with $359.1 million in net cash and cash equivalents, preserving flexibility for further investment and portfolio moves.

PYLARIFY Faces Revenue and Pricing Pressure

PYLARIFY revenue fell 9.7% year over year in Q4 to $240.2 million and declined 6.5% for the full year to $989.1 million despite volume growth. Management expects PYLARIFY net revenue to drop another 8%–10% in 2026 as pricing pressure and competitive dynamics offset usage gains.

Margins and Earnings Under Pressure

Gross margin in Q4 slipped to 65.1%, down 289 basis points from a year ago, reflecting mix shifts and cost pressures. Operating profit fell 8.5% to $138.9 million, and full‑year adjusted EPS declined 10% to $6.08, underscoring the near‑term profitability squeeze.

Cash Flow Hit by Working Capital Needs

Operating cash flow dropped to $90.2 million in Q4 from $157.7 million a year earlier, with free cash flow sliding by about $60 million to $81.4 million. Management attributed the drag to accelerated payables tied to the SPECT divestiture, timing changes in receivables, and higher inventory to support production and manufacturing expansion.

One-Time Charges Weigh on Reported Results

Adjusted figures were also impacted by $66.2 million in pre‑tax Q4 adjustments, including acquisition, integration, and divestiture expenses. Additional non‑recurring items such as non‑cash stock compensation, intangible amortization, and investment losses further distorted GAAP profitability.

Limited Near-Term Upside From 2026 Launches

Despite several PDUFA dates in 2026, Lantheus cautioned that new products will contribute little to that year’s revenue because launches and reimbursement transitions cluster late in the year. As a result, management sees the bulk of financial benefit from the new portfolio flowing in 2027 and beyond.

Pricing and Competitive Risks in PSMA

The company warned of renewed competitive pricing pressure in the PSMA imaging market, especially as rivals lose certain reimbursement advantages. Its 2026 guidance already assumes modest price erosion, but management acknowledged downside risk if competition intensifies.

Strategic Reassessment of Therapeutic Assets

Lantheus signaled that it will not heavily fund therapeutic R&D in 2026 and instead is exploring options such as partnering or divesting its radiotherapeutic assets. That strategy could unlock value but introduces uncertainty around timing, deal terms, and the ultimate contribution of these programs.

Litigation and Regulatory Overhang

The company’s outlook for PNT2003 remains tied to an expected mid‑year decision in ongoing Hatch‑Waxman litigation. Management noted that the court ruling could meaningfully influence both the timing and the long‑term economics of this radiotherapeutic opportunity.

Guidance Frames 2026 as a Reset Year

For investors, 2026 guidance underscores a reset year with revenue of $1.40–$1.45 billion versus an adjusted 2025 baseline of $1.424 billion and normalized EPS around $5.75. With PYLARIFY declining, Neuraceq growing rapidly, DEFINITY inching higher, and no major new product revenue yet, Lantheus plans to lean on its $359.1 million cash balance and stepped‑up R&D and commercial spending to position for a stronger 2027.

Lantheus’ earnings call painted a company in transition, absorbing short‑term hits to PYLARIFY, margins, and cash flow while reshaping its portfolio toward higher‑value PET diagnostics. If regulatory milestones and execution go largely to plan, management believes the groundwork laid in 2026 could support a more robust growth phase starting in 2027, but investors must navigate a choppy near term first.